Vanguard Portfolio Management Reports 5.04% Passive Stake In IDEXX

The Vanguard unit's 3,974,472 shares are held as an investment adviser, with no aim to influence control of the veterinary diagnostics company.

Share
Vanguard Portfolio Management Reports 5.04% Passive Stake In IDEXX

Vanguard Portfolio Management holds a 5.04% stake in IDEXX Laboratories, which makes diagnostic products for veterinary clinics, livestock producers and water testing, according to a passive ownership disclosure filed Friday. The position totals 3,974,472 shares.

A 5.04% position, mostly without votes

The filing lists September 30, 2026 as the triggering event and classifies Vanguard Portfolio Management as an investment adviser. Its sole voting power covers 18,545 shares, and it reports no shared voting power.

The percentage is computed on a Rule 13d-3 basis, which counts shares the holder could acquire within 60 days.

The reported holdings also include shares held by two affiliates, Vanguard Fiduciary Trust Company and Vanguard Global Advisers. The position covers Vanguard funds, or parts of them, over which the unit has dispositive power, meaning the power to decide on sales.

No intent to influence control

Vanguard certified that the shares were acquired and are held in the ordinary course of business. It said they are not held to change or influence control of IDEXX.

That certification is why the filing is a passive one rather than an activist disclosure.

IDEXX's business and its stock

IDEXX, based in Westbrook, Maine, sells in-clinic analyzers, rapid tests, reference laboratory testing and software to veterinarians. It also runs water-testing and livestock, poultry and dairy segments.

IDEXX shares traded at $555.91 in Friday trading, down 3.48% from the prior close of $575.98, and the company's market value was $45.4 billion. The stock was down 16.79% year to date as of an Oct. 28 commentary by Ricardo Pillai on Yahoo Finance, which set that against a 38.17% decline for animal-health rival Zoetis.

IDEXX's third-quarter report is the next company event. Analyst consensus ahead of it called for revenue of $1.19 billion, up 7.5% from a year earlier, and earnings of $3.71 per share.

Sources

More on IDEXX Laboratories

All IDEXX Laboratories (IDXX) coverage →